Mortality and Morbidity During a Five-year Follow-up of Diabetics with Myocardial Infarction
Overview
Affiliations
In 787 patients with acute myocardial infarction originally participating in the Göteborg Metoprolol Trial, mortality and morbidity during 5 years' follow-up were assessed and related to whether patients had diabetes mellitus. Diabetes occurred in 78 patients (10%). Patients with diabetes had a different risk factor pattern, including higher age, higher occurrence of angina pectoris and hypertension, whereas smoking habits did not differ. In the early phase (hospitalization), patients with diabetes had a higher mortality (12% versus 8%), required more treatment for heart failure and stayed longer in hospital. Other morbidity aspects, such as severity of pain, occurrence of severe supraventricular and ventricular arrhythmias, high-degree AV-block and infarct size did not differ. During 5 years' follow-up mortality rate in patients with diabetes mellitus was 55% as compared with 30% among patients with no diabetes (p less than 0.001). Reinfarction rate during 5 years was 42% in diabetics versus 25% in non-diabetics (p less than 0.001). In a multivariate analysis, taking into account the differences in risk factor pattern, diabetes turned out to be an independent determinant for long-term mortality and reinfarction (p less than 0.001). We conclude that patients with diabetes mellitus, developing acute myocardial infarction, is a group with particularly high risk of death and reinfarction. Interventions aiming at its reduction have priority.
Cardiometabolic Risk Factors Associated With Type 2 Diabetes Mellitus: A Mechanistic Insight.
Chakraborty S, Verma A, Garg R, Singh J, Verma H Clin Med Insights Endocrinol Diabetes. 2023; 16:11795514231220780.
PMID: 38148756 PMC: 10750528. DOI: 10.1177/11795514231220780.
Li Y, Guan L, Ning C, Zhang P, Zhao Y, Liu Q Cardiovasc Diabetol. 2023; 22(1):139.
PMID: 37316853 PMC: 10268354. DOI: 10.1186/s12933-023-01854-z.
Mirza A, Panchal S, Allam A, Othman S, Satia M, Mandhane S Molecules. 2022; 27(19).
PMID: 36235257 PMC: 9573038. DOI: 10.3390/molecules27196722.
Takieddin S, Alghamdi N, Mahrous M, Alamri B, Bafakeeh Q, Zahrani M Cureus. 2022; 14(6):e26113.
PMID: 35875268 PMC: 9298687. DOI: 10.7759/cureus.26113.
Carnitine Palmitoyltransferase System: A New Target for Anti-Inflammatory and Anticancer Therapy?.
Wang M, Wang K, Liao X, Hu H, Chen L, Meng L Front Pharmacol. 2021; 12:760581.
PMID: 34764874 PMC: 8576433. DOI: 10.3389/fphar.2021.760581.